



Clinical trial results:

A Randomized, Multicenter, Phase Ib/III Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared With Atezolizumab Intravenous in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Summary

EudraCT number	2018-002328-18
Trial protocol	LV PL HU GR BG IT
Global end of trial date	

Results information

Result version number	v1 (current)
This version publication date	12 May 2023
First version publication date	12 May 2023

Trial information

Trial identification

Sponsor protocol code	BP40657
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03735121
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland,
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, + 41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, + 41 616878333, genentech@druginfo.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	21 April 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	21 April 2022
Global end of trial reached?	No

Notes:

General information about the trial

Main objective of the trial:

The main purpose of Part 1 of the study is to determine the dose of atezolizumab (atezo) given as subcutaneous (SC) injection that is predicted to yield drug exposure that is comparable to that of atezolizumab intravenous (IV) infusion. The purpose of Part 2 of the study is to demonstrate non-inferiority of exposure to atezolizumab SC compared with atezolizumab IV.

Protection of trial subjects:

All participants were required to sign the informed consent form (ICF).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	21 December 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Korea, Republic of: 5
Country: Number of subjects enrolled	New Zealand: 17
Country: Number of subjects enrolled	Spain: 37
Country: Number of subjects enrolled	France: 7
Country: Number of subjects enrolled	United Kingdom: 2
Country: Number of subjects enrolled	Italy: 2
Country: Number of subjects enrolled	Latvia: 13
Country: Number of subjects enrolled	Poland: 11
Country: Number of subjects enrolled	Chile: 50
Country: Number of subjects enrolled	China: 10
Country: Number of subjects enrolled	Thailand: 69
Country: Number of subjects enrolled	Argentina: 7
Country: Number of subjects enrolled	Brazil: 22
Country: Number of subjects enrolled	Costa Rica: 8
Country: Number of subjects enrolled	Guatemala: 7
Country: Number of subjects enrolled	Mexico: 8
Country: Number of subjects enrolled	Peru: 18
Country: Number of subjects enrolled	Greece: 9
Country: Number of subjects enrolled	Hungary: 7
Country: Number of subjects enrolled	Russian Federation: 44
Country: Number of subjects enrolled	Turkey: 54
Country: Number of subjects enrolled	Ukraine: 28

Country: Number of subjects enrolled	South Africa: 3
Worldwide total number of subjects	438
EEA total number of subjects	86

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	229
From 65 to 84 years	207
85 years and over	2

Subject disposition

Recruitment

Recruitment details:

A total of 438 cancer immunotherapy (CIT)-naïve participants with non-small cell lung cancer (NSCLC) who failed prior platinum-based therapy took part in the study in 24 countries from 21 Dec 2018 to 21 Apr 2022. The study is ongoing.

Pre-assignment

Screening details:

The study has 2 parts-Part 1 and Part 2. Participants received atezolizumab [co-mixed with recombinant human hyaluronidase (rHuPH20)] at the assigned dose as SC and IV in Part 1 and atezolizumab [co-formulated with recombinant human hyaluronidase (rHuPH20)] as SC or IV in Part 2.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Part 1 Cohort 1: Atezo SC 1800 mg then Atezo 1200mg IV

Arm description:

Participants received 1800 milligrams (mg) of atezolizumab co-mixed with rHuPH20 as SC injection on Day 1 of Cycle 1 (1 cycle=21 days), followed by 1200 mg of atezolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of subsequent cycles until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.

Arm type	Experimental
Investigational medicinal product name	rHuPH20
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

rHuPH20 will be administered as per the schedule specified in the cohort 1 for Part 1.

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	RO5541267/F01
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Atezolizumab SC co-mix 1800 mg on Day 1 of Cycle 1.

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	RO5541267
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Atezolizumab IV 1200 mg, Q3W, from Day 1 Cycle 2 for all subsequent cycles.

Arm title	Part 1 Cohort 2: Atezo SC 1200 mg Q2W, then Atezo 1200mg IV
------------------	---

Arm description:

Participants received 1200 mg of atezolizumab co-mixed with rHuPH20, as SC injection, every two

weeks (Q2W), for 3 cycles (Cycle 1-3=14 days), followed by 1200 mg of atezolizumab as IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.

Arm type	Experimental
Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	RO5541267/F01
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Subcutaneous use

Dosage and administration details:

Atezolizumab SC co-mix 1200 mg Q2W for Cycles 1-3.

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	RO5541267
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Atezolizumab IV 1200 mg, Q3W, from Day 1 of Cycle 4 onwards for all subsequent cycles.

Investigational medicinal product name	rHuPH20
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

rHuPH20 will be administered as per the schedule specified in the cohort 2 for Part 1.

Arm title	Part 1 Cohort 3: Atezo SC 1800 mg Q3W then Atezo 1200 mg IV
------------------	---

Arm description:

Participants received 1800 mg of atezolizumab co-mixed with rHuPH20, as SC injection, every 3 weeks (Q3W), for 3 cycles (1 cycle=21 days), followed by 1200 mg of atezolizumab IV injection Q3W on Day 1 for subsequent cycles until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.

Arm type	Experimental
Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	RO5541267/F01
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Atezolizumab SC co-mix 1800 on Day 1 of Cycles 1-3.

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	RO5541267
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Atezolizumab IV 1200 mg, Q3W, from Day 1 of Cycle 4 onwards for all subsequent cycles.

Investigational medicinal product name	rHuPH20
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

rHuPH20 will be administered as per the schedule specified in the cohort 3 for Part 1.

Arm title	Part 2: Atezolizumab IV 1200 mg
Arm description:	
Participants will receive 1200 mg of atezolizumab, as IV infusion, Q3W, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity.	
Arm type	Experimental
Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	RO5541267/F03
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Atezolizumab IV 1200 mg Q3W on Day 1 of each 21 day cycle.

Arm title	Part 2: Atezolizumab SC 1875 mg
Arm description:	
Participants will receive 1875 mg of atezolizumab co-formulated with rHuPH20, as SC injection, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity.	
Arm type	Experimental
Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	RO5541267/F01
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Atezolizumab co-formulated with rHuPH20, SC 1875 mg Q3W on each 21 day cycle.

Number of subjects in period 1	Part 1 Cohort 1: Atezo SC 1800 mg then Atezo 1200mg IV	Part 1 Cohort 2: Atezo SC 1200 mg Q2W, then Atezo 1200mg IV	Part 1 Cohort 3: Atezo SC 1800 mg Q3W then Atezo 1200 mg IV
Started	13	15	39
Completed	6	5	1
Not completed	7	10	38
Death	3	6	8
Progressive Disease	-	-	1
Ongoing	3	3	26
Withdrawal by Subject	1	1	3
Lost to follow-up	-	-	-

Number of subjects in period 1	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg
Started	124	247
Completed	0	0
Not completed	124	247

Death	37	86
Progressive Disease	-	-
Ongoing	83	158
Withdrawal by Subject	4	2
Lost to follow-up	-	1

Baseline characteristics

Reporting groups

Reporting group title	Part 1 Cohort 1: Atezo SC 1800 mg then Atezo 1200mg IV
Reporting group description: Participants received 1800 milligrams (mg) of atezolizumab co-mixed with rHuPH20 as SC injection on Day 1 of Cycle 1 (1 cycle=21 days), followed by 1200 mg of atezolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of subsequent cycles until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	
Reporting group title	Part 1 Cohort 2: Atezo SC 1200 mg Q2W, then Atezo 1200mg IV
Reporting group description: Participants received 1200 mg of atezolizumab co-mixed with rHuPH20, as SC injection, every two weeks (Q2W), for 3 cycles (Cycle 1-3=14 days), followed by 1200 mg of atezolizumab as IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	
Reporting group title	Part 1 Cohort 3: Atezo SC 1800 mg Q3W then Atezo 1200 mg IV
Reporting group description: Participants received 1800 mg of atezolizumab co-mixed with rHuPH20, as SC injection, every 3 weeks (Q3W), for 3 cycles (1 cycle=21 days), followed by 1200 mg of atezolizumab IV injection Q3W on Day 1 for subsequent cycles until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	
Reporting group title	Part 2: Atezolizumab IV 1200 mg
Reporting group description: Participants will receive 1200 mg of atezolizumab, as IV infusion, Q3W, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity.	
Reporting group title	Part 2: Atezolizumab SC 1875 mg
Reporting group description: Participants will receive 1875 mg of atezolizumab co-formulated with rHuPH20, as SC injection, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity.	

Reporting group values	Part 1 Cohort 1: Atezo SC 1800 mg then Atezo 1200mg IV	Part 1 Cohort 2: Atezo SC 1200 mg Q2W, then Atezo 1200mg IV	Part 1 Cohort 3: Atezo SC 1800 mg Q3W then Atezo 1200 mg IV
Number of subjects	13	15	39
Age categorical Units: Subjects			

Age Continuous Units: years			
arithmetic mean	62.7	62.9	65.2
standard deviation	± 9.9	± 11.8	± 10.7
Sex: Female, Male Units: participants			
Female	8	6	12
Male	5	9	27
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	2	2	1
Native Hawaiian or Other Pacific Islander	0	0	0

Black or African American	0	0	0
White	8	11	36
More than one race	0	0	0
Unknown or Not Reported	3	2	2
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	1	5	12
Not Hispanic or Latino	9	7	25
Not Stated	3	3	2
Unknown	0	0	0

Reporting group values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg	Total
Number of subjects	124	247	438
Age categorical			
Units: Subjects			

Age Continuous			
Units: years			
arithmetic mean	64.4	62.2	
standard deviation	± 9.8	± 9.8	-
Sex: Female, Male			
Units: participants			
Female	42	72	140
Male	82	175	298
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	9	15	24
Asian	33	47	85
Native Hawaiian or Other Pacific Islander	2	1	3
Black or African American	1	2	3
White	74	174	303
More than one race	5	6	11
Unknown or Not Reported	0	2	9
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	36	61	115
Not Hispanic or Latino	88	185	314
Not Stated	0	0	8
Unknown	0	1	1

End points

End points reporting groups

Reporting group title	Part 1 Cohort 1: Atezo SC 1800 mg then Atezo 1200mg IV
Reporting group description: Participants received 1800 milligrams (mg) of atezolizumab co-mixed with rHuPH20 as SC injection on Day 1 of Cycle 1 (1 cycle=21 days), followed by 1200 mg of atezolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of subsequent cycles until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	
Reporting group title	Part 1 Cohort 2: Atezo SC 1200 mg Q2W, then Atezo 1200mg IV
Reporting group description: Participants received 1200 mg of atezolizumab co-mixed with rHuPH20, as SC injection, every two weeks (Q2W), for 3 cycles (Cycle 1-3=14 days), followed by 1200 mg of atezolizumab as IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	
Reporting group title	Part 1 Cohort 3: Atezo SC 1800 mg Q3W then Atezo 1200 mg IV
Reporting group description: Participants received 1800 mg of atezolizumab co-mixed with rHuPH20, as SC injection, every 3 weeks (Q3W), for 3 cycles (1 cycle=21 days), followed by 1200 mg of atezolizumab IV injection Q3W on Day 1 for subsequent cycles until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	
Reporting group title	Part 2: Atezolizumab IV 1200 mg
Reporting group description: Participants will receive 1200 mg of atezolizumab, as IV infusion, Q3W, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity.	
Reporting group title	Part 2: Atezolizumab SC 1875 mg
Reporting group description: Participants will receive 1875 mg of atezolizumab co-formulated with rHuPH20, as SC injection, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity.	

Primary: Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1

End point title	Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1 ^[1] ^[2]
End point description: Pharmacokinetic (PK)-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample and did not have protocol deviations that could affect PK results. Overall number analysed is the number of participants with data available for analysis.	
End point type	Primary
End point timeframe: Pre-dose on Day 1 of Cycle 2 (Cycle length=21 days for cohorts 1 and 3 and 14 days for cohort 2)	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were not planned for this endpoint. [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms.	

End point values	Part 1 Cohort 1: Atezo SC 1800 mg then Atezo 1200mg IV	Part 1 Cohort 2: Atezo SC 1200 mg Q2W, then Atezo 1200mg IV	Part 1 Cohort 3: Atezo SC 1800 mg Q3W then Atezo 1200 mg IV	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	15	35	
Units: micrograms per milli liter (µg/mL)				
geometric mean (geometric coefficient of variation)				
Ctrough at Cycle 1	121 (± 42.8)	77.5 (± 51.4)	78.3 (± 88.6)	

Statistical analyses

No statistical analyses for this end point

Primary: Part 2: Observed Serum Ctrough of Atezolizumab at Cycle 1

End point title	Part 2: Observed Serum Ctrough of Atezolizumab at Cycle 1 ^[3]
-----------------	--

End point description:

Per Protocol PK evaluable population included all participants randomized to the atezolizumab SC and atezolizumab IV treatment arms who did not have protocol deviations that could affect Cycle 1 observed Ctrough results. Overall number analyzed is the number of participants with data available for analysis.

End point type	Primary
----------------	---------

End point timeframe:

Predose on Day 1 of Cycle 2 (Cycle length=21 days for cohorts 1 and 3 and 14 days for cohort 2)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	97	205		
Units: µg/mL				
geometric mean (geometric coefficient of variation)				
Ctrough at Cycle 1	85.4 (± 34.1)	89.4 (± 127.1)		

Statistical analyses

Statistical analysis title	Analysis of Co-primary Endpoint Ctrough
-----------------------------------	---

Statistical analysis description:

The null hypothesis that atezolizumab SC is inferior to atezolizumab IV is rejected if the lower bound of the 2-sided 90% confidence interval [CI] of the geometric mean ratio is greater than or equal to (≥) the non-inferiority margin 0.8.

Comparison groups	Part 2: Atezolizumab IV 1200 mg v Part 2: Atezolizumab SC 1875 mg
-------------------	---

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Geometric mean ratio
Point estimate	1.05
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.88
upper limit	1.24

Primary: Part 2: Area Under the Concentration-Time Curve from Time Zero to 21 Days (AUC 0-21 d) at Cycle 1

End point title	Part 2: Area Under the Concentration-Time Curve from Time Zero to 21 Days (AUC 0-21 d) at Cycle 1 ^[4]
-----------------	--

End point description:

PK-evaluable population included all participants who received at least one dose of atezolizumab (atezolizumab SC or atezolizumab IV) and had at least 1 evaluable post dose PK sample. Overall number analysed is the number of participants with data available for analysis.

End point type	Primary
----------------	---------

End point timeframe:

From start of dosing up to Day 21 in Cycle 1 (Cycle length= 21 days)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	122	246		
Units: micrograms per day per mL (µg.day/mL)				
geometric mean (geometric coefficient of variation)	3327.9 (± 19.4)	2907.1 (± 35.9)		

Statistical analyses

Statistical analysis title	Analysis of Co-primary Endpoint AUC
----------------------------	-------------------------------------

Statistical analysis description:

The null hypothesis that atezolizumab SC is inferior to atezolizumab IV is rejected if the lower bound of the 2-sided 90% CI of the geometric mean ratio is greater than or equal to (\geq) the non-inferiority margin 0.8.

Comparison groups	Part 2: Atezolizumab IV 1200 mg v Part 2: Atezolizumab SC 1875 mg
-------------------	---

Number of subjects included in analysis	368
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Geometric mean ratio
Point estimate	0.87
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.83
upper limit	0.92

Secondary: Part 1: Maximum Observed Serum Concentration (Cmax) of Atezolizumab

End point title	Part 1: Maximum Observed Serum Concentration (Cmax) of Atezolizumab ^[5]
-----------------	--

End point description:

PK-evaluable population included all participants who received at least one dose of atezolizumab (atezolizumab SC or atezolizumab IV) and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analysed is the number of participants with data available for analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Predose and post dose on Day 1 of Cycle 1 and post dose on Days 3 and 8 of Cycle 1 (Cycle length = 21 days for cohorts 1 and 3 and 14 days for cohort 2)

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms.

End point values	Part 1 Cohort 1: Atezo SC 1800 mg then Atezo 1200mg IV	Part 1 Cohort 2: Atezo SC 1200 mg Q2W, then Atezo 1200mg IV	Part 1 Cohort 3: Atezo SC 1800 mg Q3W then Atezo 1200 mg IV	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	14	30	
Units: µg/mL				
geometric mean (geometric coefficient of variation)	251 (± 40.9)	129 (± 42.5)	181 (± 38.3)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Time to Maximum Serum Concentration (Tmax) of Atezolizumab

End point title	Part 1: Time to Maximum Serum Concentration (Tmax) of Atezolizumab ^[6]
-----------------	---

End point description:

PK-evaluable population included all participants who received at least one dose of atezolizumab (atezolizumab SC or atezolizumab IV) and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analysed is the number of participants with data available for analysis

End point type	Secondary
----------------	-----------

End point timeframe:

Predose and post dose on Day 1 of Cycle 1 and post dose on Days 3 and 8 of Cycle 1 (Cycle length = 21 days for cohorts 1 and 3 and 14 days for cohort 2)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms.

End point values	Part 1 Cohort 1: Atezo SC 1800 mg then Atezo 1200mg IV	Part 1 Cohort 2: Atezo SC 1200 mg Q2W, then Atezo 1200mg IV	Part 1 Cohort 3: Atezo SC 1800 mg Q3W then Atezo 1200 mg IV	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	14	30	
Units: Days				
median (full range (min-max))	3.02 (2.93 to 7.80)	3.45 (3.00 to 8.95)	3.92 (2.99 to 7.11)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Area Under the Concentration-time Curve (AUClast) of Atezolizumab

End point title	Part 1: Area Under the Concentration-time Curve (AUClast) of Atezolizumab ^[7]
-----------------	--

End point description:

PK -evaluable population included all participants who received at least one dose of atezolizumab and had atleast 1 evaluable post dose PK sample that could affect PK results. Overall number analysed is the number of participants with data available for analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Predose and up to 21 days post dose in Cycle 1 for cohorts 1 and 3 and from predose up to 14 days post last dose in Cycle 1 for cohort 2 (Cycle length= 21 days for cohorts 1 and 3 and 14 days for cohort 2)

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is specific for Part 1 and hence included only Part 1 arms.

End point values	Part 1 Cohort 1: Atezo SC 1800 mg then Atezo 1200mg IV	Part 1 Cohort 2: Atezo SC 1200 mg Q2W, then Atezo 1200mg IV	Part 1 Cohort 3: Atezo SC 1800 mg Q3W then Atezo 1200 mg IV	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	14	30	
Units: day*ug/mL				
geometric mean (geometric coefficient of variation)				
AUClast at Cycle 1	3870 (± 38.6)	1410 (± 41.8)	2820 (± 38.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration

End point title	Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration ^[8]
-----------------	---

End point description:

PK-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Here 99999 indicates participants were not analysed for this endpoint at the given timepoint; 9999 indicates the data was not evaluable as all the samples were below lower limit of quantification (BLQ). Cohorts 1,3 cycle length =21days; cohort 2=14days. Overall number analysed is the number of participants with data available for analysis at a specified timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 1: Pre&postdose:D1 &postdose: D3,8 of C1; Cohort 2: Pre&postdose: D1 of C1,3 & postdose: D3,8 of C1, Predose: D1 of C2; Cohort 3: Pre& postdose: D1 of C1,2 & postdose: D3,8 of C1, D2,4& 9 of C2& pre dose:D1 of C3

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 1 and hence included only Part 1 arms.

End point values	Part 1 Cohort 1: Atezo SC 1800 mg then Atezo 1200mg IV	Part 1 Cohort 2: Atezo SC 1200 mg Q2W, then Atezo 1200mg IV	Part 1 Cohort 3: Atezo SC 1800 mg Q3W then Atezo 1200 mg IV	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	15	39	
Units: µg/mL				
geometric mean (geometric coefficient of variation)				
Cycle 1, Day 1: Pre-dose (13,15,39)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	
Cycle 1, Day 1: Post-dose (13,15,39)	116 (± 57.8)	61.7 (± 70.9)	108 (± 57.6)	
Cycle 1, Day 3: Post-dose (13,15,38)	247 (± 40.5)	123 (± 44.3)	166 (± 45.7)	
Cycle 1, Day 8: Post-dose (13,15,37)	230 (± 36.6)	110 (± 45.0)	162 (± 43.5)	
Cycle 2, Day 1: Pre-dose (0,15,35)	99999 (± 99999)	77.5 (± 51.4)	78.3 (± 88.6)	
Cycle 2, Day 1: Post-dose (0,0,36)	99999 (± 99999)	99999 (± 99999)	87.7 (± 64.7)	
Cycle 2, Day 2: Post-dose (0,0,36)	99999 (± 99999)	99999 (± 99999)	183 (± 46.1)	
Cycle 2, Day 4: Post-dose (0,0,34)	99999 (± 99999)	99999 (± 99999)	245 (± 42.0)	
Cycle 2, Day 9: Post-dose (0,0,35)	99999 (± 99999)	99999 (± 99999)	225 (± 37.2)	
Cycle 3, Day 1: pre-dose (0,14,33)	99999 (± 99999)	104 (± 47.8)	123 (± 57.2)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Model Predicted Ctrough of Atezolizumab at Cycle 1

End point title	Part 2: Model Predicted Ctrough of Atezolizumab at Cycle 1 ^[9]
-----------------	---

End point description:

PK-evaluable population included all participants who received at least one dose of atezolizumab (atezolizumab SC or atezolizumab IV) and had at least 1 evaluable post dose PK sample. Overall number analysed is the number of participants with data available for analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 (Cycle length =21 days for cohorts 1 and 3 and 14 days for cohort 2).

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	122	246		
Units: µg/mL				
geometric mean (geometric coefficient of variation)	88.7 (± 26.2)	97.2 (± 42.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Participants with Adverse Events (AEs)

End point title	Part 1: Percentage of Participants with Adverse Events (AEs) ^[10]
-----------------	--

End point description:

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 5.0 (NCI-CTCAE, v5.0). Safety-evaluable population included all participants who received at least one dose of atezolizumab (atezolizumab SC or atezolizumab IV)

End point type	Secondary
----------------	-----------

End point timeframe:

From signing of informed consent form (ICF) until 30 days after last dose of study drug administration in Part 1 (Up to approximately 15 months)

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 1 and hence included only Part 1 arms.

End point values	Part 1 Cohort 1: Atezo SC 1800 mg then Atezo 1200mg IV	Part 1 Cohort 2: Atezo SC 1200 mg Q2W, then Atezo 1200mg IV	Part 1 Cohort 3: Atezo SC 1800 mg Q3W then Atezo 1200 mg IV	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	13	31	
Units: Percentage of Participants				
number (not applicable)	100	86.7	79.5	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Participants with AEs

End point title	Part 2: Percentage of Participants with AEs ^[11]
-----------------	---

End point description:

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 5.0 (NCI-CTCAE, v5.0). Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

From signing of informed consent form (ICF) until 30 days after last dose of study drug administration in Part 2 (Up to approximately 72 months)

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms. Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[12]	0 ^[13]		
Units: Percentage of Participants				
number (not applicable)				

Notes:

[12] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

[13] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Model Predicted Ctrough at steady State (Cthrough,ss) of Atezolizumab

End point title	Part 2: Model Predicted Ctrough at steady State (Cthrough,ss) of Atezolizumab ^[14]
-----------------	---

End point description:

PK-evaluable population included all participants who received at least one dose of atezolizumab (atezolizumab SC or atezolizumab IV) and had at least 1 evaluable post dose PK sample. Overall number analysed is the number of participants with data available for analysis

End point type	Secondary
----------------	-----------

End point timeframe:

Atezo SC: Pre & postdose C1D1, postdose C1 Days 2,4,8, Predose C2,D1 and Predose C3,4,8,12 and 16 D1; Atezo IV: pre and postdose of C1D1, postdose C1 Days 2,4,8; Pre and postdose C2D1, Predose at C3,4,8,12, and 16 (up to approximately 16 months)

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	122	246		
Units: µg/mL				
geometric mean (geometric coefficient of variation)	179 (± 38.8)	205 (± 58.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Model Predicted AUC at steady State (AUCss) of Atezolizumab

End point title	Part 2: Model Predicted AUC at steady State (AUCss) of Atezolizumab ^[15]
-----------------	---

End point description:

PK-evaluable population included all participants who received at least one dose of atezolizumab (atezolizumab SC or atezolizumab IV) and had at least 1 evaluable post dose PK sample. Overall number analysed is the number of participants with data available for analysis

End point type	Secondary
----------------	-----------

End point timeframe:

Atezo SC: Pre & postdose C1D1, postdose C1 Days 2,4,8, Predose C2,D1 and Predose C3,4,8,12 and 16 D1; Atezo IV: pre and postdose of C1D1, postdose C1 Days 2,4,8; Pre and postdose C2D1, Predose at C3,4,8,12, and 16 (up to approximately 16 months)

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	122	246		
Units: µg.day/mL				
geometric mean (geometric coefficient of variation)	6107 (± 27.3)	6163 (± 46.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Progression-Free Survival (PFS)

End point title	Part 2: Progression-Free Survival (PFS) ^[16]
-----------------	---

End point description:

PFS is defined as the time from randomization to the first documented progressive disease per RECIST v1.1 or death due to any cause, whichever occurs first. Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

From study start to the first occurrence of disease progression or death from any cause, whichever occurs first (Up to approximately 72 months).

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms. Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[17]	0 ^[18]		
Units: months				
number (confidence interval 95%)	(to)	(to)		

Notes:

[17] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

[18] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Overall Survival (OS)

End point title	Part 2: Overall Survival (OS) ^[19]
-----------------	---

End point description:

OS defined as the time from study entry to death from any cause. Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

From study start to death from any cause (Up to approximately 72 months)

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms. Data collection is

ongoing and results will be disclosed within 1 year from Study Completion Date.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[20]	0 ^[21]		
Units: months				
number (confidence interval 95%)	(to)	(to)		

Notes:

[20] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

[21] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Duration of response (DOR)

End point title	Part 2: Duration of response (DOR) ^[22]
-----------------	--

End point description:

DOR is defined as the time from first occurrence of a documented objective response to disease progression as determined by the investigator according to RECIST v1.1. or death from any cause, whichever occurs first. Objective response is defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per RECIST v1.1. CR is the disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to < 10 mm. PR is defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the Baseline sum diameters in the absence of CR. Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

From first occurrence of documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 72 months)

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms. Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[23]	0 ^[24]		
Units: months				
number (confidence interval 95%)	(to)	(to)		

Notes:

[23] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

[24] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Objective Response Rate (ORR)

End point title	Part 2: Objective Response Rate (ORR) ^[25]
-----------------	---

End point description:

ORR is defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. CR is the disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to < 10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the Baseline sum diameters in the absence of CR. Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

From treatment initiation until disease progression or loss of clinical benefit (Up to approximately 72 months).

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms. Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[26]	0 ^[27]		
Units: percentage of participants				
number (confidence interval 95%)	(to)	(to)		

Notes:

[26] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

[27] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Overall Patient-reported AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item from the EORTC IL57

End point title	Part 2: Overall Patient-reported AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item from the EORTC IL57 ^[28]
-----------------	---

End point description:

The overall patient-reported AE burden was assessed using the a single item from the EORTC IL57 questionnaire i.e To what extent have you been troubled with side-effects from your treatment?. The questions is answered on a 4-point Likert scale where 1="Not at all" to 4="Very much". Higher scores indicates greater AE burden. Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 of Cycles 1-6 and then every other cycle up to treatment discontinuation visit (Up to approximately 72 months)

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms. Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[29]	0 ^[30]		
Units: score on a scale				
arithmetic mean (standard deviation)	()	()		

Notes:

[29] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

[30] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Functioning and Global Health Status Over Time, as assessed by European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL)57

End point title	Part 2: Functioning and Global Health Status Over Time, as assessed by European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL)57 ^[31]
-----------------	---

End point description:

EORTC IL57 questionnaire has 10 items and covers 3 scales: physical functioning (PF), role functioning (RF) & global health status/quality of life (GHS/QoL) & 1 item from EORTC Item Library. PF scale has 5 items evaluating the extent to which participants have trouble doing strenuous activities; taking long walks & short walks; need to stay in bed or a chair; need help with eating, dressing, bathing/using toilet. RF scale has 2 items evaluating extent to which participants are limited in doing work & pursuing leisure activities in previous week. GHS/QoL scale has 2 items evaluating participants' overall health & QoL in previous week. Questions are answered on a 4-point Likert scale (where 1="Not at all" to 4="Very much") for physical and role functioning & a 7-point scale (where 1="Very poor" to 7="Excellent") for GHS/QoL. For each scale, mean of the items are linearly transformed to obtain scores from 0-100, where 100 =best possible score. Higher score = better outcome.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 of Cycles 1-6 and then every other cycle up to treatment discontinuation visit (Up to approximately 72 months)

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms. Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[32]	0 ^[33]		
Units: score on a scale				
number (not applicable)				

Notes:

[32] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

[33] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Overall Satisfaction with Treatment Over Time, Assessed by the Modified Satisfaction with Therapy (SWT) Scale of the Cancer Therapy Satisfaction Questionnaire (CTSQ)

End point title	Part 2: Overall Satisfaction with Treatment Over Time, Assessed by the Modified Satisfaction with Therapy (SWT) Scale of the Cancer Therapy Satisfaction Questionnaire (CTSQ) ^[34]
-----------------	---

End point description:

Modified SWT scale of the CTSQ consist of seven items that measures seven domains related to satisfaction with cancer therapy. These include worthwhile, difficulty, benefits, feelings about side effects, form, of therapy, overall satisfaction, and if participants would choose the therapy taking everything into consideration. Each domain is rated on a 5-point scale, with 1 representing the worst response and 5 representing the best response, except in the case of one reverse-scored item. mean of the items are linearly transformed to obtain scores from 0-100, where 100 =best possible score Higher scores are associated with higher satisfaction. Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 Cycle 3 or at treatment discontinuation visit (Up to approximately 72 months)

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms. Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[35]	0 ^[36]		
Units: score on a scale				
arithmetic mean (standard deviation)	()	()		

Notes:

[35] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

[36] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Participants with Ant-Drug Antibodies (ADAs) to Atezolizumab After SC or IV Administration

End point title	Part 2: Percentage of Participants with Ant-Drug Antibodies (ADAs) to Atezolizumab After SC or IV Administration ^[37]
-----------------	--

End point description:

Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of atezolizumab up to treatment discontinuation visit (Up to approximately 72 Months).

Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms. Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[38]	0 ^[39]		
Units: percentage of participants				
number (not applicable)				

Notes:

[38] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

[39] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Participants with ADAs to rHuPH20 After SC Administration Relative to the Prevalence of ADAs at Baseline

End point title	Part 2: Percentage of Participants with ADAs to rHuPH20 After SC Administration Relative to the Prevalence of ADAs at Baseline ^[40]
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of atezolizumab up to treatment discontinuation visit (Up to approximately 72 Months)

Notes:

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms. Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[41]	0 ^[42]		
Units: percentage of participants				
number (not applicable)				

Notes:

[41] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

[42] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Convenience, Ease of Administration, and Overall Satisfaction with Atezolizumab SC Assessed Using HCP Subcutaneous Perspective Questionnaire

End point title	Part 2: Convenience, Ease of Administration, and Overall Satisfaction with Atezolizumab SC Assessed Using HCP Subcutaneous Perspective Questionnaire ^[43]
-----------------	--

End point description:

The HCP Subcutaneous Perspective Questionnaire consists of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 72 months)

Notes:

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms. Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[44]	0 ^[45]		
Units: participants				
number (not applicable)				

Notes:

[44] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

[45] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Convenience, Potential Time Savings, and Overall Satisfaction with Atezolizumab SC Compared with Atezolizumab IV as Assessed Using HCP Subcutaneous Versus IV Perspective Questionnaire

End point title	Part 2: Convenience, Potential Time Savings, and Overall Satisfaction with Atezolizumab SC Compared with Atezolizumab IV as Assessed Using HCP Subcutaneous Versus IV Perspective Questionnaire ^[46]
-----------------	---

End point description:

HCP Subcutaneous Versus IV Perspective Questionnaire consists of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction. Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 72 months)

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific for Part 2 and hence included only Part 2 arms. Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

End point values	Part 2: Atezolizumab IV 1200 mg	Part 2: Atezolizumab SC 1875 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[47]	0 ^[48]		
Units: participants				
number (not applicable)				

Notes:

[47] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

[48] - Data collection is ongoing and results will be disclosed within 1 year from Study Completion Date.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From signing of ICF to primary completion date (Up to approximately 40 months)

Adverse event reporting additional description:

Safety-evaluable population included all participants who received at least one dose of atezolizumab (atezolizumab SC or atezolizumab IV).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.1
--------------------	------

Reporting groups

Reporting group title	Part 1 Cohort 1: Atezo SC 1800 mg Co-mix
-----------------------	--

Reporting group description:

Participants received 1800 mg of atezolizumab co-mixed with rHuPH20, as SC injection on Day 1 of Cycle 1 (1 cycle=21 days), followed by 1200 mg of atezolizumab as IV infusion Q3W on Day 1 of subsequent cycles until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.

Reporting group title	Part 1 Cohort 2: Atezolizumab SC 1200mg, Q2W, Co-mix
-----------------------	--

Reporting group description:

Participants received 1200 mg of atezolizumab co-mixed with rHuPH20, as SC injection, every two weeks (Q2W) on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by 1200 mg of atezolizumab as IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.

Reporting group title	Part 2: Atezolizumab SC 1875 mg
-----------------------	---------------------------------

Reporting group description:

Participants will receive 1875 mg of atezolizumab co-formulated with rHuPH20, as SC injection, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity.

Reporting group title	Part 2: Atezolizumab IV 1200 mg
-----------------------	---------------------------------

Reporting group description:

Participants will receive 1200 mg of atezolizumab, as IV infusion, Q3W, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity.

Reporting group title	Part 1 Cohort 3: Atezolizumab SC 1800 mg, Q3W, Co-mix
-----------------------	---

Reporting group description:

Participants received 1800 mg of atezolizumab co-mixed with rHuPH20, as SC injection, every 3 weeks (Q3W) on Day 1, for 3 cycles (1 cycle=21 days), followed by 1200 mg of atezolizumab IV injection Q3W on Day 1 for subsequent cycles until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.

Serious adverse events	Part 1 Cohort 1: Atezo SC 1800 mg Co-mix	Part 1 Cohort 2: Atezolizumab SC 1200mg, Q2W, Co- mix	Part 2: Atezolizumab SC 1875 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 13 (15.38%)	4 / 15 (26.67%)	38 / 247 (15.38%)
number of deaths (all causes)	3	6	86
number of deaths resulting from adverse events	0	0	2
Vascular disorders			
Orthostatic Hypotension			

subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest Pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	2 / 247 (0.81%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural Effusion			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	2 / 247 (0.81%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Haemoptysis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary Embolism			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Pulmonary Oedema			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	2 / 247 (0.81%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Aspartate Aminotransferase Increased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood Sodium Decreased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alanine Aminotransferase Increased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Infusion Related Reaction			

subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip Fracture			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head Injury			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiac disorders			
Myocardial Infarction			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	4 / 247 (1.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 3
Arrhythmia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac Failure Congestive			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute Coronary Syndrome			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular Accident			
subjects affected / exposed	1 / 13 (7.69%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Ischaemic Stroke			

subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	2 / 247 (0.81%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Transient Ischaemic Attack			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic Infarction			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal Pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Diarrhoea			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal Pain			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Immune-Mediated Hepatitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Toxic Epidermal Necrolysis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Rash Maculo-Papular			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Tubulointerstitial Nephritis			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back Pain			

subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Vascular Device Infection			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 15 (0.00%)	5 / 247 (2.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Covid-19			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung Abscess			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Bacterial			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper Respiratory Tract Infection			

subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Aspiration			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	2 / 247 (0.81%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 2
Covid-19 Pneumonia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	4 / 247 (1.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Tracheobronchitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis Jirovecii Pneumonia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bronchitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis Infectious			

subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory Tract Infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 2: Atezolizumab IV 1200 mg	Part 1 Cohort 3: Atezolizumab SC 1800 mg, Q3W, Co-mix	
Total subjects affected by serious adverse events			
subjects affected / exposed	22 / 124 (17.74%)	9 / 39 (23.08%)	
number of deaths (all causes)	37	8	
number of deaths resulting from adverse events	0	0	
Vascular disorders			
Orthostatic Hypotension			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest Pain			

subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	2 / 124 (1.61%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural Effusion			
subjects affected / exposed	2 / 124 (1.61%)	1 / 39 (2.56%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary Embolism			

subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary Oedema			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Aspartate Aminotransferase Increased			
subjects affected / exposed	0 / 124 (0.00%)	1 / 39 (2.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood Sodium Decreased			
subjects affected / exposed	0 / 124 (0.00%)	1 / 39 (2.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alanine Aminotransferase Increased			
subjects affected / exposed	0 / 124 (0.00%)	1 / 39 (2.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Infusion Related Reaction			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip Fracture			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Head Injury			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Myocardial Infarction			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac Failure Congestive			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute Coronary Syndrome			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebrovascular Accident			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic Stroke			
subjects affected / exposed	0 / 124 (0.00%)	1 / 39 (2.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Transient Ischaemic Attack			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic Infarction			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Cataract			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal Pain			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	0 / 124 (0.00%)	1 / 39 (2.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			

subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal Pain			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Immune-Mediated Hepatitis			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Toxic Epidermal Necrolysis			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash Maculo-Papular			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Tubulointerstitial Nephritis			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back Pain			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Vascular Device Infection			

subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	4 / 124 (3.23%)	1 / 39 (2.56%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Covid-19			
subjects affected / exposed	3 / 124 (2.42%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lung Abscess			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia Bacterial			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary Tract Infection			
subjects affected / exposed	2 / 124 (1.61%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper Respiratory Tract Infection			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pneumonia Aspiration			

subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Covid-19 Pneumonia			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumocystis Jirovecii Pneumonia			
subjects affected / exposed	0 / 124 (0.00%)	1 / 39 (2.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis Infectious			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory Tract Infection			

subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 124 (0.00%)	1 / 39 (2.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypokalaemia			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Part 1 Cohort 1: Atezo SC 1800 mg Co-mix	Part 1 Cohort 2: Atezolizumab SC 1200mg, Q2W, Co- mix	Part 2: Atezolizumab SC 1875 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 13 (100.00%)	12 / 15 (80.00%)	193 / 247 (78.14%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hair Follicle Tumour Benign			
subjects affected / exposed	1 / 13 (7.69%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences (all)	0	0	1
Venous Thrombosis Limb			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	0 / 247 (0.00%)
occurrences (all)	0	1	0
General disorders and administration			

site conditions			
Injection Site Reaction			
subjects affected / exposed	3 / 13 (23.08%)	1 / 15 (6.67%)	4 / 247 (1.62%)
occurrences (all)	3	1	10
Oedema			
subjects affected / exposed	1 / 13 (7.69%)	0 / 15 (0.00%)	1 / 247 (0.40%)
occurrences (all)	1	0	1
Injection Site Inflammation			
subjects affected / exposed	1 / 13 (7.69%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	1 / 13 (7.69%)	2 / 15 (13.33%)	25 / 247 (10.12%)
occurrences (all)	2	2	26
Gait Disturbance			
subjects affected / exposed	1 / 13 (7.69%)	0 / 15 (0.00%)	2 / 247 (0.81%)
occurrences (all)	1	0	3
Chills			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	1 / 247 (0.40%)
occurrences (all)	0	2	1
Asthenia			
subjects affected / exposed	5 / 13 (38.46%)	3 / 15 (20.00%)	16 / 247 (6.48%)
occurrences (all)	5	3	16
Injection Site Erythema			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	1 / 247 (0.40%)
occurrences (all)	0	1	1
Chest Pain			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	9 / 247 (3.64%)
occurrences (all)	0	2	11
Pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	4 / 247 (1.62%)
occurrences (all)	0	0	4
Mucosal Inflammation			
subjects affected / exposed	1 / 13 (7.69%)	1 / 15 (6.67%)	0 / 247 (0.00%)
occurrences (all)	1	1	0
Pyrexia			

subjects affected / exposed occurrences (all)	3 / 13 (23.08%) 3	1 / 15 (6.67%) 1	10 / 247 (4.05%) 12
Oedema Peripheral subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	3 / 247 (1.21%) 3
Injection Site Pain subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 15 (0.00%) 0	6 / 247 (2.43%) 8
Respiratory, thoracic and mediastinal disorders			
Dyspnoea subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	2 / 15 (13.33%) 2	22 / 247 (8.91%) 22
Haemoptysis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 15 (13.33%) 2	3 / 247 (1.21%) 3
Dyspnoea Exertional subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	1 / 247 (0.40%) 1
Dysphonia subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 15 (6.67%) 1	2 / 247 (0.81%) 2
Chronic Obstructive Pulmonary Disease subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 15 (13.33%) 4	0 / 247 (0.00%) 0
Pulmonary Embolism subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	0 / 247 (0.00%) 0
Pleuritic Pain subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	0 / 247 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	5 / 13 (38.46%) 6	3 / 15 (20.00%) 3	23 / 247 (9.31%) 26
Productive Cough			

subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 15 (6.67%) 1	4 / 247 (1.62%) 4
Psychiatric disorders			
Insomnia			
subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	1 / 15 (6.67%) 1	8 / 247 (3.24%) 8
Investigations			
Aspartate Aminotransferase Increased			
subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 15 (13.33%) 2	17 / 247 (6.88%) 17
Lipase Increased			
subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	2 / 15 (13.33%) 2	0 / 247 (0.00%) 0
Weight Decreased			
subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 15 (6.67%) 1	8 / 247 (3.24%) 11
Alanine Aminotransferase Increased			
subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 15 (0.00%) 0	17 / 247 (6.88%) 17
Blood Sodium Decreased			
subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 15 (0.00%) 0	1 / 247 (0.40%) 1
Blood Alkaline Phosphatase Increased			
subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	13 / 247 (5.26%) 13
Blood Albumin Decreased			
subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 15 (0.00%) 0	0 / 247 (0.00%) 0
Blood Triglycerides Increased			
subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	0 / 247 (0.00%) 0
Amylase Increased			
subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 15 (13.33%) 2	0 / 247 (0.00%) 0
Platelet Count Decreased			

subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences (all)	0	0	0
Blood Thyroid Stimulating Hormone Increased			
subjects affected / exposed	1 / 13 (7.69%)	0 / 15 (0.00%)	2 / 247 (0.81%)
occurrences (all)	1	0	2
Blood Creatinine Increased			
subjects affected / exposed	1 / 13 (7.69%)	1 / 15 (6.67%)	1 / 247 (0.40%)
occurrences (all)	1	1	1
Blood Lactate Dehydrogenase Increased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	9 / 247 (3.64%)
occurrences (all)	0	0	9
Blood Cholesterol Increased			
subjects affected / exposed	0 / 13 (0.00%)	3 / 15 (20.00%)	0 / 247 (0.00%)
occurrences (all)	0	3	0
Blood Magnesium Decreased			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	0 / 247 (0.00%)
occurrences (all)	0	1	0
Neutrophil Count Increased			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	0 / 247 (0.00%)
occurrences (all)	0	1	0
Gamma-Glutamyltransferase Increased			
subjects affected / exposed	0 / 13 (0.00%)	2 / 15 (13.33%)	6 / 247 (2.43%)
occurrences (all)	0	2	6
Haemoglobin Decreased			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	0 / 247 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Procedural Pain			
subjects affected / exposed	1 / 13 (7.69%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Supraventricular Tachycardia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	1 / 247 (0.40%)
occurrences (all)	0	1	1

Tachycardia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	1 / 247 (0.40%) 1
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	0 / 15 (0.00%) 0	10 / 247 (4.05%) 11
Dizziness subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	3 / 247 (1.21%) 3
Dysgeusia subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	0 / 15 (0.00%) 0	1 / 247 (0.40%) 1
Tremor subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	1 / 247 (0.40%) 1
Sensory Loss subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	0 / 247 (0.00%) 0
Neuropathy Peripheral subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	1 / 247 (0.40%) 1
Blood and lymphatic system disorders			
Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	7 / 247 (2.83%) 9
Leukocytosis subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	2 / 247 (0.81%) 2
Anaemia subjects affected / exposed occurrences (all)	3 / 13 (23.08%) 3	5 / 15 (33.33%) 5	37 / 247 (14.98%) 40
Lymphopenia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	7 / 247 (2.83%) 8
Eye disorders			

Periorbital Oedema subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	0 / 247 (0.00%) 0
Gastrointestinal disorders			
Anal Haemorrhage subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	0 / 247 (0.00%) 0
Dry Mouth subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	2 / 247 (0.81%) 3
Dyspepsia subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	3 / 247 (1.21%) 3
Vomiting subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	2 / 15 (13.33%) 2	7 / 247 (2.83%) 7
Abdominal Pain subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	0 / 15 (0.00%) 0	9 / 247 (3.64%) 9
Diarrhoea subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	0 / 15 (0.00%) 0	11 / 247 (4.45%) 11
Nausea subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	3 / 15 (20.00%) 4	14 / 247 (5.67%) 14
Gastrooesophageal Reflux Disease subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 15 (0.00%) 0	1 / 247 (0.40%) 1
Constipation subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	2 / 15 (13.33%) 2	14 / 247 (5.67%) 14
Skin and subcutaneous tissue disorders			
Rash subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 15 (6.67%) 1	9 / 247 (3.64%) 11
Alopecia			

subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	1 / 247 (0.40%) 1
Rash Erythematous subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	0 / 247 (0.00%) 0
Dry Skin subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	3 / 247 (1.21%) 3
Pruritus subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	8 / 247 (3.24%) 8
Renal and urinary disorders Renal Failure subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	0 / 247 (0.00%) 0
Acute Kidney Injury subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	3 / 247 (1.21%) 3
Endocrine disorders Hyperthyroidism subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	2 / 15 (13.33%) 2	6 / 247 (2.43%) 6
Hypothyroidism subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 15 (13.33%) 2	13 / 247 (5.26%) 13
Musculoskeletal and connective tissue disorders Back Pain subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	2 / 15 (13.33%) 3	16 / 247 (6.48%) 16
Pain In Extremity subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	10 / 247 (4.05%) 12
Muscle Spasms subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 15 (6.67%) 1	2 / 247 (0.81%) 2
Arthralgia			

subjects affected / exposed	1 / 13 (7.69%)	1 / 15 (6.67%)	15 / 247 (6.07%)
occurrences (all)	1	2	18
Musculoskeletal Chest Pain			
subjects affected / exposed	1 / 13 (7.69%)	1 / 15 (6.67%)	3 / 247 (1.21%)
occurrences (all)	1	1	3
Musculoskeletal Pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	9 / 247 (3.64%)
occurrences (all)	0	1	10
Joint Swelling			
subjects affected / exposed	1 / 13 (7.69%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	11 / 247 (4.45%)
occurrences (all)	0	1	13
Covid-19			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	12 / 247 (4.86%)
occurrences (all)	0	0	12
Urinary Tract Infection			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	8 / 247 (3.24%)
occurrences (all)	0	2	9
Furuncle			
subjects affected / exposed	1 / 13 (7.69%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences (all)	1	0	0
Bronchitis			
subjects affected / exposed	1 / 13 (7.69%)	1 / 15 (6.67%)	2 / 247 (0.81%)
occurrences (all)	1	1	2
Folliculitis			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	0 / 247 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	0 / 13 (0.00%)	2 / 15 (13.33%)	0 / 247 (0.00%)
occurrences (all)	0	2	0

Vestibular Neuronitis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	0 / 247 (0.00%) 0
Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	0 / 15 (0.00%) 0	4 / 247 (1.62%) 4
Laryngitis subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	0 / 247 (0.00%) 0
Asymptomatic Bacteriuria subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 2	0 / 247 (0.00%) 0
Viral Infection subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	0 / 247 (0.00%) 0
Metabolism and nutrition disorders			
Hypomagnesaemia subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	0 / 15 (0.00%) 0	6 / 247 (2.43%) 7
Hypoalbuminaemia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	11 / 247 (4.45%) 12
Hyponatraemia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	3 / 15 (20.00%) 3	14 / 247 (5.67%) 14
Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	7 / 247 (2.83%) 8
Hypokalaemia subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 15 (0.00%) 0	3 / 247 (1.21%) 3
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 15 (6.67%) 1	2 / 247 (0.81%) 2
Vitamin D Deficiency			

subjects affected / exposed	1 / 13 (7.69%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences (all)	1	0	0
Hypercreatininaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	3 / 247 (1.21%)
occurrences (all)	0	0	5
Dehydration			
subjects affected / exposed	0 / 13 (0.00%)	1 / 15 (6.67%)	2 / 247 (0.81%)
occurrences (all)	0	2	2
Hyperkalaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 15 (0.00%)	8 / 247 (3.24%)
occurrences (all)	0	0	9
Decreased Appetite			
subjects affected / exposed	1 / 13 (7.69%)	3 / 15 (20.00%)	24 / 247 (9.72%)
occurrences (all)	1	3	25
Vitamin B12 Deficiency			
subjects affected / exposed	1 / 13 (7.69%)	0 / 15 (0.00%)	0 / 247 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Part 2: Atezolizumab IV 1200 mg	Part 1 Cohort 3: Atezolizumab SC 1800 mg, Q3W, Co- mix	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	88 / 124 (70.97%)	29 / 39 (74.36%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hair Follicle Tumour Benign			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 124 (1.61%)	2 / 39 (5.13%)	
occurrences (all)	3	2	
Venous Thrombosis Limb			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
General disorders and administration site conditions			

Injection Site Reaction		
subjects affected / exposed	0 / 124 (0.00%)	2 / 39 (5.13%)
occurrences (all)	0	4
Oedema		
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)
occurrences (all)	0	0
Injection Site Inflammation		
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)
occurrences (all)	0	0
Fatigue		
subjects affected / exposed	17 / 124 (13.71%)	9 / 39 (23.08%)
occurrences (all)	17	10
Gait Disturbance		
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)
occurrences (all)	0	0
Chills		
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)
occurrences (all)	0	0
Asthenia		
subjects affected / exposed	6 / 124 (4.84%)	6 / 39 (15.38%)
occurrences (all)	6	6
Injection Site Erythema		
subjects affected / exposed	0 / 124 (0.00%)	1 / 39 (2.56%)
occurrences (all)	0	1
Chest Pain		
subjects affected / exposed	8 / 124 (6.45%)	1 / 39 (2.56%)
occurrences (all)	8	2
Pain		
subjects affected / exposed	2 / 124 (1.61%)	2 / 39 (5.13%)
occurrences (all)	2	2
Mucosal Inflammation		
subjects affected / exposed	0 / 124 (0.00%)	1 / 39 (2.56%)
occurrences (all)	0	1
Pyrexia		
subjects affected / exposed	5 / 124 (4.03%)	1 / 39 (2.56%)
occurrences (all)	6	1

Oedema Peripheral subjects affected / exposed occurrences (all)	1 / 124 (0.81%) 1	2 / 39 (5.13%) 2	
Injection Site Pain subjects affected / exposed occurrences (all)	0 / 124 (0.00%) 0	2 / 39 (5.13%) 2	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea subjects affected / exposed occurrences (all)	15 / 124 (12.10%) 16	3 / 39 (7.69%) 3	
Haemoptysis subjects affected / exposed occurrences (all)	2 / 124 (1.61%) 2	3 / 39 (7.69%) 3	
Dyspnoea Exertional subjects affected / exposed occurrences (all)	0 / 124 (0.00%) 0	0 / 39 (0.00%) 0	
Dysphonia subjects affected / exposed occurrences (all)	1 / 124 (0.81%) 1	1 / 39 (2.56%) 1	
Chronic Obstructive Pulmonary Disease subjects affected / exposed occurrences (all)	0 / 124 (0.00%) 0	0 / 39 (0.00%) 0	
Pulmonary Embolism subjects affected / exposed occurrences (all)	1 / 124 (0.81%) 1	0 / 39 (0.00%) 0	
Pleuritic Pain subjects affected / exposed occurrences (all)	0 / 124 (0.00%) 0	0 / 39 (0.00%) 0	
Cough subjects affected / exposed occurrences (all)	7 / 124 (5.65%) 7	5 / 39 (12.82%) 5	
Productive Cough subjects affected / exposed occurrences (all)	2 / 124 (1.61%) 2	0 / 39 (0.00%) 0	
Psychiatric disorders			

Insomnia			
subjects affected / exposed	8 / 124 (6.45%)	0 / 39 (0.00%)	
occurrences (all)	8	0	
Investigations			
Aspartate Aminotransferase Increased			
subjects affected / exposed	7 / 124 (5.65%)	3 / 39 (7.69%)	
occurrences (all)	7	4	
Lipase Increased			
subjects affected / exposed	0 / 124 (0.00%)	3 / 39 (7.69%)	
occurrences (all)	0	3	
Weight Decreased			
subjects affected / exposed	5 / 124 (4.03%)	0 / 39 (0.00%)	
occurrences (all)	5	0	
Alanine Aminotransferase Increased			
subjects affected / exposed	4 / 124 (3.23%)	2 / 39 (5.13%)	
occurrences (all)	5	2	
Blood Sodium Decreased			
subjects affected / exposed	0 / 124 (0.00%)	3 / 39 (7.69%)	
occurrences (all)	0	3	
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	5 / 124 (4.03%)	2 / 39 (5.13%)	
occurrences (all)	5	2	
Blood Albumin Decreased			
subjects affected / exposed	0 / 124 (0.00%)	2 / 39 (5.13%)	
occurrences (all)	0	2	
Blood Triglycerides Increased			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Amylase Increased			
subjects affected / exposed	0 / 124 (0.00%)	3 / 39 (7.69%)	
occurrences (all)	0	4	
Platelet Count Decreased			
subjects affected / exposed	1 / 124 (0.81%)	3 / 39 (7.69%)	
occurrences (all)	1	4	
Blood Thyroid Stimulating Hormone Increased			

subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences (all)	1	0	
Blood Creatinine Increased			
subjects affected / exposed	4 / 124 (3.23%)	1 / 39 (2.56%)	
occurrences (all)	4	1	
Blood Lactate Dehydrogenase Increased			
subjects affected / exposed	4 / 124 (3.23%)	2 / 39 (5.13%)	
occurrences (all)	4	2	
Blood Cholesterol Increased			
subjects affected / exposed	0 / 124 (0.00%)	2 / 39 (5.13%)	
occurrences (all)	0	2	
Blood Magnesium Decreased			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Neutrophil Count Increased			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Gamma-Glutamyltransferase Increased			
subjects affected / exposed	4 / 124 (3.23%)	0 / 39 (0.00%)	
occurrences (all)	4	0	
Haemoglobin Decreased			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Injury, poisoning and procedural complications			
Procedural Pain			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Cardiac disorders			
Supraventricular Tachycardia			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Tachycardia			
subjects affected / exposed	0 / 124 (0.00%)	1 / 39 (2.56%)	
occurrences (all)	0	1	
Nervous system disorders			

Headache			
subjects affected / exposed	5 / 124 (4.03%)	0 / 39 (0.00%)	
occurrences (all)	5	0	
Dizziness			
subjects affected / exposed	2 / 124 (1.61%)	3 / 39 (7.69%)	
occurrences (all)	2	3	
Dysgeusia			
subjects affected / exposed	0 / 124 (0.00%)	1 / 39 (2.56%)	
occurrences (all)	0	1	
Tremor			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Sensory Loss			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Neuropathy Peripheral			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences (all)	1	0	
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	5 / 124 (4.03%)	0 / 39 (0.00%)	
occurrences (all)	5	0	
Leukocytosis			
subjects affected / exposed	2 / 124 (1.61%)	0 / 39 (0.00%)	
occurrences (all)	2	0	
Anaemia			
subjects affected / exposed	18 / 124 (14.52%)	12 / 39 (30.77%)	
occurrences (all)	21	13	
Lymphopenia			
subjects affected / exposed	2 / 124 (1.61%)	0 / 39 (0.00%)	
occurrences (all)	2	0	
Eye disorders			
Periorbital Oedema			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			

Anal Haemorrhage			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Dry Mouth			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Dyspepsia			
subjects affected / exposed	3 / 124 (2.42%)	0 / 39 (0.00%)	
occurrences (all)	3	0	
Vomiting			
subjects affected / exposed	3 / 124 (2.42%)	2 / 39 (5.13%)	
occurrences (all)	3	2	
Abdominal Pain			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences (all)	1	0	
Diarrhoea			
subjects affected / exposed	3 / 124 (2.42%)	2 / 39 (5.13%)	
occurrences (all)	4	2	
Nausea			
subjects affected / exposed	2 / 124 (1.61%)	8 / 39 (20.51%)	
occurrences (all)	2	10	
Gastrooesophageal Reflux Disease			
subjects affected / exposed	0 / 124 (0.00%)	2 / 39 (5.13%)	
occurrences (all)	0	2	
Constipation			
subjects affected / exposed	5 / 124 (4.03%)	1 / 39 (2.56%)	
occurrences (all)	5	1	
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	8 / 124 (6.45%)	1 / 39 (2.56%)	
occurrences (all)	9	1	
Alopecia			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Rash Erythematous			

subjects affected / exposed occurrences (all)	1 / 124 (0.81%) 1	0 / 39 (0.00%) 0	
Dry Skin subjects affected / exposed occurrences (all)	0 / 124 (0.00%) 0	1 / 39 (2.56%) 1	
Pruritus subjects affected / exposed occurrences (all)	10 / 124 (8.06%) 11	4 / 39 (10.26%) 4	
Renal and urinary disorders Renal Failure subjects affected / exposed occurrences (all)	0 / 124 (0.00%) 0	0 / 39 (0.00%) 0	
Acute Kidney Injury subjects affected / exposed occurrences (all)	0 / 124 (0.00%) 0	0 / 39 (0.00%) 0	
Endocrine disorders Hyperthyroidism subjects affected / exposed occurrences (all)	1 / 124 (0.81%) 1	0 / 39 (0.00%) 0	
Hypothyroidism subjects affected / exposed occurrences (all)	4 / 124 (3.23%) 6	0 / 39 (0.00%) 0	
Musculoskeletal and connective tissue disorders Back Pain subjects affected / exposed occurrences (all)	7 / 124 (5.65%) 7	2 / 39 (5.13%) 2	
Pain In Extremity subjects affected / exposed occurrences (all)	5 / 124 (4.03%) 5	1 / 39 (2.56%) 1	
Muscle Spasms subjects affected / exposed occurrences (all)	1 / 124 (0.81%) 1	1 / 39 (2.56%) 1	
Arthralgia subjects affected / exposed occurrences (all)	5 / 124 (4.03%) 6	4 / 39 (10.26%) 4	
Musculoskeletal Chest Pain			

subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal Pain			
subjects affected / exposed	0 / 124 (0.00%)	3 / 39 (7.69%)	
occurrences (all)	0	3	
Myalgia			
subjects affected / exposed	1 / 124 (0.81%)	4 / 39 (10.26%)	
occurrences (all)	1	4	
Joint Swelling			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Infections and infestations			
Pneumonia			
subjects affected / exposed	2 / 124 (1.61%)	1 / 39 (2.56%)	
occurrences (all)	2	1	
Covid-19			
subjects affected / exposed	8 / 124 (6.45%)	0 / 39 (0.00%)	
occurrences (all)	8	0	
Urinary Tract Infection			
subjects affected / exposed	5 / 124 (4.03%)	0 / 39 (0.00%)	
occurrences (all)	5	0	
Furuncle			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Bronchitis			
subjects affected / exposed	1 / 124 (0.81%)	2 / 39 (5.13%)	
occurrences (all)	1	2	
Folliculitis			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Nasopharyngitis			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	
Vestibular Neuronitis			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	

Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	2 / 124 (1.61%) 2	2 / 39 (5.13%) 2	
Laryngitis subjects affected / exposed occurrences (all)	0 / 124 (0.00%) 0	0 / 39 (0.00%) 0	
Asymptomatic Bacteriuria subjects affected / exposed occurrences (all)	0 / 124 (0.00%) 0	0 / 39 (0.00%) 0	
Viral Infection subjects affected / exposed occurrences (all)	0 / 124 (0.00%) 0	0 / 39 (0.00%) 0	
Metabolism and nutrition disorders			
Hypomagnesaemia subjects affected / exposed occurrences (all)	7 / 124 (5.65%) 8	3 / 39 (7.69%) 3	
Hypoalbuminaemia subjects affected / exposed occurrences (all)	4 / 124 (3.23%) 5	2 / 39 (5.13%) 2	
Hyponatraemia subjects affected / exposed occurrences (all)	12 / 124 (9.68%) 15	4 / 39 (10.26%) 4	
Hyperglycaemia subjects affected / exposed occurrences (all)	10 / 124 (8.06%) 13	2 / 39 (5.13%) 2	
Hypokalaemia subjects affected / exposed occurrences (all)	4 / 124 (3.23%) 4	0 / 39 (0.00%) 0	
Hypercalcaemia subjects affected / exposed occurrences (all)	6 / 124 (4.84%) 7	0 / 39 (0.00%) 0	
Vitamin D Deficiency subjects affected / exposed occurrences (all)	0 / 124 (0.00%) 0	0 / 39 (0.00%) 0	
Hypercreatininaemia			

subjects affected / exposed	8 / 124 (6.45%)	0 / 39 (0.00%)	
occurrences (all)	9	0	
Dehydration			
subjects affected / exposed	1 / 124 (0.81%)	0 / 39 (0.00%)	
occurrences (all)	1	0	
Hyperkalaemia			
subjects affected / exposed	8 / 124 (6.45%)	3 / 39 (7.69%)	
occurrences (all)	10	3	
Decreased Appetite			
subjects affected / exposed	10 / 124 (8.06%)	6 / 39 (15.38%)	
occurrences (all)	11	6	
Vitamin B12 Deficiency			
subjects affected / exposed	0 / 124 (0.00%)	0 / 39 (0.00%)	
occurrences (all)	0	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 June 2019	<p>Subcutaneous site of first drug administration for Cohort 3 was changed from thigh to abdomen to accommodate patient convenience, increased patient privacy, and possible administration of higher drug volume.</p> <p>Study drug dosage for Cohort 3 was changed from 2400 mg Q4W to 1800 mg Q3W to assess the alternate administration site (abdomen).</p> <p>Enrollment for Cohort 3 was increased to approximately 20-30 patients to provide enough participants who could be assessed for feasibility of abdominal administration.</p>
30 March 2020	No changes impacted study conduct.
28 August 2020	A randomized control arm comprising of patients treated with atezolizumab IV as per standard of care was added in Part 2. Investigational treatment in Part 2 was modified to atezolizumab monotherapy and inclusion criteria modified to include patients in whom platinum therapy had failed, to allow for assessment of atezolizumab SC without confounding factors associated with use in combination with chemotherapy.
10 February 2021	<p>Subcutaneous site of first drug administration for Cohort 3 was changed from thigh to abdomen to accommodate patient convenience, increased patient privacy, and possible administration of higher drug volume. Study drug dosage for Cohort 3 was changed from 2400 mg Q4W to 1800 mg Q3W to assess the alternate administration site (abdomen).</p> <p>Enrollment for Cohort 3 was increased to approximately 20-30 patients to provide enough patients who could be assessed for feasibility of abdominal administration.</p>
25 February 2022	<p>Amendment 1: 1. Adverse event management guidelines have been updated to align with the atezolizumab investigator's brochure, version 18. 2. References to an extended recruitment in China have been removed. 3. Estimand language in Section 6.6.2 has been corrected to match the definition of Per Protocol PK analysis population provided in Section 6.2.2. 4. Benefit-risk assessment and guidance on concomitant administration of severe acute respiratory syndrome coronavirus 2 vaccines with atezolizumab has been added. 5. Medical term "primary biliary cirrhosis" has been replaced by the term "primary biliary cholangitis" to align with the updated preferred term in MedDRA. 6. Responsibilities of the Principal Investigator and the role of the medical monitor in determining patient eligibility have been clarified. 7. Other minor changes.</p>

07 February 2023	<p>The medical term “Wegener granulomatosis” has been replaced by the term “granulomatosis with polyangiitis” to align with the updated preferred term in MedDRA.</p> <ul style="list-style-type: none"> • The list of identified risks for atezolizumab has been revised to include pericardial disorders. • The list of identified risks for atezolizumab has been revised to include myelitis and facial paresis. • Hemophagocytic lymphohistiocytosis has been updated from a potential risk to an identified risk associated with atezolizumab and language has been revised accordingly. • The list of adverse events of special interest has been revised to include myelitis and facial paresis. • A description of the technical and organizational security measures taken to protect personal data has been added to align with CTR requirements. • Appendix 8 has been revised to indicate that caution should be used when considering atezolizumab for participants who have previously experienced a pericardial disorder while receiving another immunostimulatory anti-cancer agent. • Appendix 8 has been revised to include autoimmune myelitis. • The adverse event management guidelines have been updated to align with the Addendum 1 and the Addendum 2 to the Atezolizumab Investigator’s Brochure, Version 19.
------------------	--

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported